Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsSector news 

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2013 | 12:07pm CET

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at hendrik.varnholt@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
02:47p MONSANTO COMPANY : - Leading Independent Proxy Advisory Firms ISS and Glass Lewi..
12/05 COVESTRO : Assigned Patent
12/02 BAYER : Sources Sought - Preventive Maintenance & service solution on existing B..
12/02 BAYER : Sources Sought Notice - J-- Preventive Maintenance & service solution on..
11/24 BAYER : supports public access to safety-relevant crop protection study reports
11/23 Global Milnacipran HCl Market 2016- Pfizer Inc (US), Bayer HealthCare Pharmac..
11/22 BAYER : Announces Phase III Study to Evaluate New Pediatric Formulation of Nifur..
11/21 Global Polyurethane Market - DOW Chemical Company, Bayer AG, Sekisui Chemical..
11/21 COVESTRO : Assigned Patent
11/18 Global Polyols Market - BASF SE, Mitsui Chemicals, Inc., Bayer AG, Chemtura C..
More news
Sector news : Pharmaceuticals - NEC
05:58pDJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
05:58pDJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/05 Monsanto Acquisition Has Driven Bayer Deep Into Value Territory
12/05 Precision AML Trial Adds Pharma Candidates To The Mix
12/05 J&J Target Offers Over 20% Upside
11/30 A Guide To Investing In Water
11/29 Blueprint's candidate for advanced liver cancer shows anti-tumor activity in ..
Financials (€)
Sales 2016 46 747 M
EBIT 2016 8 627 M
Net income 2016 4 732 M
Debt 2016 16 430 M
Yield 2016 3,04%
P/E ratio 2016 15,44
P/E ratio 2017 13,71
EV / Sales 2016 1,91x
EV / Sales 2017 1,76x
Capitalization 72 895 M
More Financials
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 107 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-24.74%78 298
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
More Results